ClinicalTrials.gg
CompletedNCT02826603CLARITYUpdated Jul 9, 2019Results posted

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

A Phase 3 interventional study of Secukinumab and Ustekinumab in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 155 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
4th of 54
1,114 · median 124
Started
2016
with 3 others
Phase 3
24 of 54
none open now
Registered
32nd of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 32nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque psoriasis
  • secukinumab
  • ustekinumab
  • ain457
  • ain457a
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must give a written, signed and dated
  • Chronic plaque-type psoriasis present for at least 6 months before randomization
  • Moderate to severe plaque psoriasis as defined at randomization by:

    • PASI score of ≥12 and
    • Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and
    • IGA mod 2011 ≥3 (based on a scale of 0-4)
  • Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:

    • Topical treatment (including topical ) and/or
    • Phototherapy and/or
    • Previous systemic therapy

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than plaque psoriasis
  • Drug-induced psoriasis
  • Ongoing use of prohibited treatments
  • Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23
  • Use of any other drugs within 5 half-lives of the investigational treatment before study drug initiation
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,114 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Secukinumab

    Drug: Secukinumab

  • Active comparator
    Ustekinumab

    Ustekinumab

    Drug: Ustekinumab

Interventions

  • 300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48

  • Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.

06

What researchers measure

Primary outcomes

  1. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12

    Number of participants who achieved ≥ 90% reduction in PASI compared to baseline. Logistic regression analysis of PASI 90 response at Week 12 PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).

    Time frame: Week 12

  2. Participants With IGA Mod 2011 0 or 1 at Week 12

    Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

    Time frame: Week 12

Secondary outcomes

  1. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12

    Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.

    Time frame: Week 12

  2. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4

    Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.

    Time frame: Week 4

  3. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16

    Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.

    Time frame: Week 16

  4. Participants With IGA Mod 2011 0 or 1 at 16 Weeks

    Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

    Time frame: Week 16

  5. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12

    Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.

    Time frame: Week 12

  6. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

    Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.

    Time frame: Week 16

  7. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.

    Time frame: Week 16

  8. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52

    Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.

    Time frame: Week 52

07

Results

Posted Jul 9, 2019

Participant flow

Overall, 1353 patients were screened of which 1102 patients completed the Screening phase; 251 patients were screen failures

Participant flow — Overall Study
MilestoneSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Started550552
Completed489488
Not completed6164
Withdrew: Adverse event179
Withdrew: Lack of efficacy49
Withdrew: Lost to follow-up1312
Withdrew: Noncompliance with treatment02
Withdrew: Physician decision17
Withdrew: Pregnancy12
Withdrew: Protocol violation33
Withdrew: Withdrawal by subject2019
Withdrew: Death20
Withdrew: New therapy for study indication01

Outcome measures

PrimaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12

Number of participants who achieved ≥ 90% reduction in PASI compared to baseline. Logistic regression analysis of PASI 90 response at Week 12 PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12366265
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.21 · 95% CI 1.72 to 2.84
PrimaryParticipants With IGA Mod 2011 0 or 1 at Week 12

Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Participants With IGA Mod 2011 0 or 1 at Week 12
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants With IGA Mod 2011 0 or 1 at Week 12397306
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.10 · 95% CI 1.63 to 2.72
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12

Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12484409
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.62 · 95% CI 1.89 to 3.62
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4

Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 422190
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.53 · 95% CI 2.65 to 4.71
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16

Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16250147
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.33 · 95% CI 1.80 to 3.01
SecondaryParticipants With IGA Mod 2011 0 or 1 at 16 Weeks

Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants With IGA Mod 2011 0 or 1 at 16 Weeks
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants With IGA Mod 2011 0 or 1 at 16 Weeks432326
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.57 · 95% CI 1.96 to 3.37
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12

Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12210111
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.50 · 95% CI 1.89 to 3.31
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16506441
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.86 · 95% CI 1.96 to 4.17
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16423299
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.85 · 95% CI 2.19 to 3.71
SecondaryParticipants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52

Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52
ParticipantsSecukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mg
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52402330
Statistical analysis
  • Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 1.84 · 95% CI 1.41 to 2.41

Adverse events

Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 months. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300 mg2/550 (0.4%)29/550 (5.3%)216/550 (39.3%)
UST 45/90 mg0/552 (0%)21/552 (3.8%)229/552 (41.5%)
All Patients2/1,102 (0.2%)50/1,102 (4.5%)445/1,102 (40.4%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventAIN457 300 mgUST 45/90 mgAll Patients
Atrial fibrillationCardiac disorders3/5500/5523/1102
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/5500/5523/1102
Ventricular tachycardiaCardiac disorders2/5500/5522/1102
Dengue feverInfections and infestations2/5500/5522/1102
Deep vein thrombosisVascular disorders2/5501/5523/1102
CellulitisInfections and infestations1/5502/5523/1102
LymphadenopathyBlood and lymphatic system disorders1/5500/5521/1102
Angina pectorisCardiac disorders1/5500/5521/1102
Myocardial ischaemiaCardiac disorders1/5500/5521/1102
Anal fissureGastrointestinal disorders1/5500/5521/1102
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAIN457 300 mgUST 45/90 mgAll Patients
Upper respiratory tract infectionInfections and infestations49/55061/552110/1102
NasopharyngitisInfections and infestations55/55054/552109/1102
DiarrhoeaGastrointestinal disorders26/55024/55250/1102
HeadacheNervous system disorders26/55025/55251/1102
SinusitisInfections and infestations25/55018/55243/1102
HypertensionVascular disorders17/55022/55239/1102
Back painMusculoskeletal and connective tissue disorders14/55020/55234/1102
BronchitisInfections and infestations8/55018/55226/1102
PruritusSkin and subcutaneous tissue disorders12/55018/55230/1102
CoughRespiratory, thoracic and mediastinal disorders17/55016/55233/1102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Secukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mgTotal
Mean45.4 ± 14.0945.3 ± 14.1645.4 ± 14.12
Age, Customized
Age, Customized(Participants)Secukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mgTotal
<65 years488494982
>=65 years and <75 years6048108
>=75 years21012
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mgTotal
Female194176370
Male356376732
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 300mg (2 x 150 mg)Ustekinumab 2 x 45mg or 90mgTotal
Caucasian416410826
Black212445
Asian6057117
Native American344175
Pacific Islander156
Unknown426
Other141327
08

Study locations

155 sites
  • Novartis Investigative Site
    Anniston, Alabama 36207, United States
  • Novartis Investigative Site
    Birmingham, Alabama 35205, United States
  • Novartis Investigative Site
    Birmingham, Alabama 35233, United States
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Glendale, Arizona 85308, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85018, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85032, United States
  • Novartis Investigative Site
    Scottsdale, Arizona 85259, United States
  • Novartis Investigative Site
    Scottsdale, Arizona 85260, United States
  • Novartis Investigative Site
    Tucson, Arizona 85724, United States
  • Novartis Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Novartis Investigative Site
    Hot Springs, Arkansas 71913, United States
  • Novartis Investigative Site
    Rogers, Arkansas 72758, United States
  • Novartis Investigative Site
    Bakersfield, California 93309, United States
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    California City, California 93405, United States
  • Novartis Investigative Site
    Encinitas, California 92024, United States
  • Novartis Investigative Site
    Fresno, California 93710, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Irvine, California 92697, United States
  • Novartis Investigative Site
    Los Angeles, California 90033, United States
  • Novartis Investigative Site
    Oceanside, California 92056, United States
  • Novartis Investigative Site
    Sacramento, California 95819, United States
  • Novartis Investigative Site
    San Diego, California 92103, United States
  • Novartis Investigative Site
    San Diego, California 92117, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    Santa Monica, California 90404, United States
  • Novartis Investigative Site
    Santa Rosa, California 95405, United States
  • Novartis Investigative Site
    Denver, Colorado 80220, United States
  • Novartis Investigative Site
    Trumbull, Connecticut 06611, United States
  • Novartis Investigative Site
    Aventura, Florida 33180, United States
  • Novartis Investigative Site
    Boca Raton, Florida 33486, United States
  • Novartis Investigative Site
    Cape Coral, Florida 33990, United States
  • Novartis Investigative Site
    Coral Gables, Florida 33134, United States
  • Novartis Investigative Site
    Fort Myers, Florida 33916, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32216, United States
  • Novartis Investigative Site
    Orange Park, Florida 32073, United States
  • Novartis Investigative Site
    South Miami, Florida 33143, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Tampa, Florida 33624, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33409, United States
  • Novartis Investigative Site
    Alpharetta, Georgia 30022, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30342, United States
  • Novartis Investigative Site
    Macon, Georgia 31217, United States
  • Novartis Investigative Site
    Marietta, Georgia 30060, United States
  • Novartis Investigative Site
    Newnan, Georgia 30263, United States
  • Novartis Investigative Site
    Skokie, Illinois 60077, United States
  • Novartis Investigative Site
    Springfield, Illinois 62703, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    New Albany, Indiana 47150, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40241, United States
  • Novartis Investigative Site
    Owensboro, Kentucky 42301, United States
  • Novartis Investigative Site
    Owensboro, Kentucky 42303, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Novartis Investigative Site
    Lake Charles, Louisiana 70601, United States
  • Novartis Investigative Site
    Lake Charles, Louisiana 70605, United States
  • Novartis Investigative Site
    Metairie, Louisiana 70006, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70112, United States
  • Novartis Investigative Site
    Rockville, Maryland 20850, United States
  • Novartis Investigative Site
    Rockville, Maryland 20852, United States
  • Novartis Investigative Site
    Beverly, Massachusetts 01915, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Brighton, Massachusetts 02135, United States
  • Novartis Investigative Site
    Quincy, Massachusetts 02169, United States
  • Novartis Investigative Site
    Fridley, Minnesota 55432, United States
  • Novartis Investigative Site
    Jackson, Mississippi 39216-4505, United States
  • Novartis Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63104, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63117, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89128, United States
  • Novartis Investigative Site
    East Windsor, New Jersey 08520, United States
  • Novartis Investigative Site
    Verona, New Jersey 07044, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87106, United States
  • Novartis Investigative Site
    Forest Hills, New York 11375, United States
  • Novartis Investigative Site
    New York, New York 10016, United States
  • Novartis Investigative Site
    New York, New York 10025 1737, United States
  • Novartis Investigative Site
    New York, New York 10075, United States
  • Novartis Investigative Site
    Rochester, New York 14623, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27516, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28209, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27401, United States
  • Novartis Investigative Site
    High Point, North Carolina 27262, United States
  • Novartis Investigative Site
    Rocky Mount, North Carolina 27804, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45242, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106-5028, United States
  • Novartis Investigative Site
    Columbus, Ohio 43210, United States
  • Novartis Investigative Site
    Dublin, Ohio 43016, United States
  • Novartis Investigative Site
    Fairborn, Ohio 45324, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73103, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Oregon City, Oregon 97045, United States
  • Novartis Investigative Site
    Portland, Oregon 97210, United States
  • Novartis Investigative Site
    Portland, Oregon 97223, United States
  • Novartis Investigative Site
    Exton, Pennsylvania 19341, United States
  • Novartis Investigative Site
    Jenkintown, Pennsylvania 19046, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213-3403, United States

Showing the first 100 of 155 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Alpalhao M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann CE, Kasparek T, Filipe P. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region. BioDrugs. 2022 Nov;36(6):781-789. doi: 10.1007/s40259-022-00558-2. Epub 2022 Nov 5. PubMed 36334236 ↗
  • Conrad C, Ortmann CE, Vandemeulebroecke M, Kasparek T, Reich K. Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2022 Jan;12(1):233-241. doi: 10.1007/s13555-021-00654-1. Epub 2021 Dec 6. PubMed 34870789 ↗
  • Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8. PubMed 32365251 ↗
  • Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579. doi: 10.1007/s13555-018-0265-y. Epub 2018 Oct 17. PubMed 30334147 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jul 2018, 24 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2015
First posted
Jul 11, 2016
StartActual
Jun 22, 2016
Primary completionActual
Jul 9, 2018
CompletionActual
Jul 9, 2018
Results first posted
Jul 9, 2019
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02826603
Responsible party
Sponsor
First posted
Jul 11, 2016
Start date
Jun 22, 2016
Primary completion
Jul 9, 2018
Completion
Jul 9, 2018
Results posted
Jul 9, 2019
Last update
Jul 9, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion